Grifols Partnership is a CDMO focused on added value injectable products, with a large international experience in the development and manufacturing of sterile drug products (small molecules) in glass vials and PP bags. Strict compliance with global manufacturing standards has earned us the highest accreditations, including authorizations by the US FDA, EU and US GMP and authorization for parametric release sterility.
Andrew Kolbert of Avomeen discusses FDA oversight of E&L testing, complications that arise, and the expertise needed to keep up with changing quality standards
Underscores potential for momelotinib to address unmet needs of patients with Intermediate/High-Risk myelofibrosis who have previously received a JAK inhibitor
Contract Pharma asked a roundtable of business leaders from Symbiosis, Grifols, Althea, LSNE and Baxter to discuss key trends in the parenteral dosage development and manufacturing market